{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:14:25Z","timestamp":1791648865862,"version":"4.3.4"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03612-5","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:44:15Z","timestamp":1777542255000},"page":"2852-2870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low-Dose Naltrexone: What is the Evidence? A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5325-2382","authenticated-orcid":false,"given":"Amina H. K.","family":"Gouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9250-8846","authenticated-orcid":false,"given":"Nicholas E. C.","family":"Aitcheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-330X","authenticated-orcid":false,"given":"Kathryn J.","family":"Steadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"3612_CR1","unstructured":"Singh D, Saadabadi A. Naltrexone. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 [updated 2025 Jan; cited 2026 Feb 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534811\/."},{"key":"3612_CR2","unstructured":"Substance Abuse and Mental Health Services Administration; Center for Substance Abuse Treatment. Incorporating alcohol pharmacotherapies into medical practice. Treatment improvement protocol (TIP) series 49. Rockville (MD): US Department of Health and Human Services; 2009."},{"key":"3612_CR3","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1073\/pnas.90.12.5391","volume":"90","author":"MJ Brownstein","year":"1993","unstructured":"Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci U S A. 1993;90:5391\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3612_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0026-895X(25)09190-4","volume":"36","author":"A Goldstein","year":"1989","unstructured":"Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol. 1989;36:265\u201372.","journal-title":"Mol Pharmacol"},{"key":"3612_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00002826-199302000-00001","volume":"16","author":"GW Pasternak","year":"1993","unstructured":"Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16:1\u201318.","journal-title":"Clin Neuropharmacol"},{"key":"3612_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/0306-4522(82)90027-6","volume":"7","author":"TV Dunwiddie","year":"1982","unstructured":"Dunwiddie TV, Perez-Reyes E, Rice KC, Palmer MR. Stereoselectivity of opiate antagonists in rat hippocampus and neocortex: responses to (+) and (\u2212) isomers of naloxone. Neuroscience. 1982;7:1691\u2013702.","journal-title":"Neuroscience"},{"key":"3612_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/apc.1995.9.3","volume":"9","author":"B Bihari","year":"1995","unstructured":"Bihari B. Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV\/AIDS. AIDS Patient Care STDS. 1995;9:3.","journal-title":"AIDS Patient Care STDS"},{"key":"3612_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/JPR.S451183","volume":"17","author":"NJ Marcus","year":"2024","unstructured":"Marcus NJ, Robbins L, Araki A, Gracely EJ, Theoharides TC. Effective doses of low-dose naltrexone for chronic pain\u2014an observational study. J Pain Res. 2024;17:1273\u201384.","journal-title":"J Pain Res"},{"key":"3612_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/bph.13394","volume":"173","author":"X Wang","year":"2016","unstructured":"Wang X, Zhang Y, Peng Y, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016;173:856\u201369.","journal-title":"Br J Pharmacol"},{"key":"3612_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1021\/acs.jcim.7b00717","volume":"58","author":"X Zhang","year":"2018","unstructured":"Zhang X, Cui F, Chen H, et al. Dissecting the innate immune recognition of opioid inactive isomer (+)-naltrexone derived toll-like receptor 4 (TLR4) antagonists. J Chem Inf Model. 2018;58:816\u201325.","journal-title":"J Chem Inf Model"},{"key":"3612_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/1535370218817746","volume":"243","author":"IS Zagon","year":"2018","unstructured":"Zagon IS, McLaughlin PJ. Intermittent blockade of OGFr and treatment of autoimmune disorders. Exp Biol Med (Maywood). 2018;243:1323\u201330.","journal-title":"Exp Biol Med (Maywood)"},{"key":"3612_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1258\/ebm.2011.011121","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood). 2011;236:1036\u201350.","journal-title":"Exp Biol Med (Maywood)"},{"key":"3612_CR13","first-page":"e81086","volume":"17","author":"KK Leiber","year":"2025","unstructured":"Leiber KK, Parker RW. Therapeutic uses and efficacy of low-dose naltrexone: a scoping review. Cureus. 2025;17:e81086.","journal-title":"Cureus"},{"key":"3612_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.31128\/AJGP-09-22-6564","volume":"52","author":"N Aitcheson","year":"2023","unstructured":"Aitcheson N, Lin Z, Tynan K. Low-dose naltrexone in the treatment of fibromyalgia: a systematic review and narrative synthesis. Aust J Gen Pract. 2023;52:189\u201395.","journal-title":"Aust J Gen Pract"},{"key":"3612_CR15","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1371\/journal.pone.0001554","volume":"3","author":"HY Wang","year":"2008","unstructured":"Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin A prevents Mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS ONE. 2008;3:e1554.","journal-title":"PLoS ONE"},{"key":"3612_CR16","doi-asserted-by":"publisher","first-page":"e4282","DOI":"10.1371\/journal.pone.0004282","volume":"4","author":"HY Wang","year":"2009","unstructured":"Wang HY, Burns LH. Naloxone\u2019s pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS ONE. 2009;4:e4282.","journal-title":"PLoS ONE"},{"key":"3612_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","volume":"10","author":"J Younger","year":"2009","unstructured":"Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10:663\u201372.","journal-title":"Pain Med"},{"key":"3612_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.37734","volume":"65","author":"J Younger","year":"2013","unstructured":"Younger J, Noor N, McCue R, MacKey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65:529\u201338.","journal-title":"Arthritis Rheum"},{"key":"3612_CR19","first-page":"409","volume":"73","author":"TMHD Paula","year":"2023","unstructured":"Paula TMHD, Castro MS, Medeiros LF, et al. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial. Braz J Anesthesiol. 2023;73:409\u201317.","journal-title":"Braz J Anesthesiol"},{"key":"3612_CR20","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1097\/PR9.0000000000001080","volume":"8","author":"K Bested","year":"2023","unstructured":"Bested K, Jensen LM, Andresen T, et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study. Pain Rep. 2023;8:e1080.","journal-title":"Pain Rep"},{"key":"3612_CR21","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","volume":"6","author":"K Due Bruun","year":"2024","unstructured":"Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6:e31\u20139.","journal-title":"Lancet Rheumatol"},{"key":"3612_CR22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/1753-0407.13202","volume":"13","author":"A Srinivasan","year":"2021","unstructured":"Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13:770\u20138.","journal-title":"J Diabetes"},{"key":"3612_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clinthera.2023.03.013","volume":"45","author":"B Beaudette-Zlatanova","year":"2023","unstructured":"Beaudette-Zlatanova B, Lew RA, Otis JD, et al. Pilot study of low-dose naltrexone for the treatment of chronic pain due to arthritis: a randomized, double-blind, placebo-controlled, crossover clinical trial. Clin Ther. 2023;45:468\u201377.","journal-title":"Clin Ther"},{"key":"3612_CR24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/09540121.2021.1896663","volume":"35","author":"S Bendiks","year":"2023","unstructured":"Bendiks S, Cheng DM, Blokhina E, et al. Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial. AIDS Care. 2023;35:1191\u2013200.","journal-title":"AIDS Care"},{"key":"3612_CR25","doi-asserted-by":"publisher","first-page":"e0297948","DOI":"10.1371\/journal.pone.0297948","volume":"19","author":"JI Tsui","year":"2024","unstructured":"Tsui JI, Rossi SL, Cheng DM, et al. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. PLoS ONE. 2024;19:e0297948.","journal-title":"PLoS ONE"},{"key":"3612_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2217\/pmt-2021-0122","volume":"12","author":"SJ Martin","year":"2022","unstructured":"Martin SJ, McAnally HB, Okediji P, Rogosnitzky M. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study. Pain Manag. 2022;12:699\u2013709.","journal-title":"Pain Manag"},{"key":"3612_CR27","first-page":"119","volume":"15","author":"C Roehmer","year":"2022","unstructured":"Roehmer C, Deshpande K, Khan S, Navlani R, Chu A. Low-dose naltrexone for treatment of refractory chronic pain. J Pain Manag. 2022;15:119\u201323.","journal-title":"J Pain Manag"},{"key":"3612_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jtos.2020.12.003","volume":"20","author":"G Dieckmann","year":"2021","unstructured":"Dieckmann G, Ozmen MC, Cox SM, Engert RC, Hamrah P. Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain. Ocul Surf. 2021;20:33\u20138.","journal-title":"Ocul Surf"},{"key":"3612_CR29","doi-asserted-by":"publisher","first-page":"593842","DOI":"10.3389\/fpsyt.2021.593842","volume":"12","author":"D Jackson","year":"2021","unstructured":"Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021;12:593842.","journal-title":"Front Psychiatry"},{"key":"3612_CR30","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2147\/JPR.S389957","volume":"16","author":"AM McKenzie-Brown","year":"2023","unstructured":"McKenzie-Brown AM, Singh V, Boorman DW, Ibanez KR, Agwu E. Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series. J Pain Res. 2023;16:1993\u20138.","journal-title":"J Pain Res"},{"key":"3612_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/15360288.2024.2358941","volume":"38","author":"J Pogue","year":"2024","unstructured":"Pogue J, Johnson D, Burch A. A utilization review of patients that respond to low-dose naltrexone (LDN) for chronic pain at a single institution. J Pain Palliat Care Pharmacother. 2024;38:406\u201313.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"3612_CR32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/15360288.2025.2456279","volume":"39","author":"A Spargo","year":"2025","unstructured":"Spargo A, Gonser L, Faley B. Evaluation of low-dose naltrexone for chronic pain management. J Pain Palliat Care Pharmacother. 2025;39:319\u201322.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"3612_CR33","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.2147\/JPR.S561662","volume":"18","author":"H Aalto","year":"2025","unstructured":"Aalto H, Paul S, McEwen V. Real-world effectiveness and tolerability of low dose naltrexone to treat chronic pain: a retrospective cohort study of one pain physician\u2019s practice. J Pain Res. 2025;18:6637\u201349.","journal-title":"J Pain Res"},{"key":"3612_CR34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/biomedicines11041087","volume":"11","author":"CN Driver","year":"2023","unstructured":"Driver CN, D\u2019Souza RS. Efficacy of low-dose naltrexone and predictors of treatment success or discontinuation in fibromyalgia and other chronic pain conditions: a fourteen-year, enterprise-wide retrospective analysis. Biomedicines. 2023;11:1087.","journal-title":"Biomedicines"},{"key":"3612_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/15360288.2024.2302550","volume":"38","author":"MN Irwin","year":"2024","unstructured":"Irwin MN, Cooke DA, Berland D, Marshall VD, Smith MA. Efficacy and safety of low dose naltrexone for chronic pain. J Pain Palliat Care Pharmacother. 2024;38:13\u20139.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"3612_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.psym.2011.11.006","volume":"53","author":"S Ramanathan","year":"2012","unstructured":"Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics. 2012;53:591\u20134.","journal-title":"Psychosomatics"},{"key":"3612_CR37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s11481-013-9451-y","volume":"8","author":"P Chopra","year":"2013","unstructured":"Chopra P, Cooper MS. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharmacol. 2013;8:470\u20136.","journal-title":"J Neuroimmune Pharmacol"},{"key":"3612_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/pm\/pnv009","volume":"17","author":"D Hota","year":"2016","unstructured":"Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A. Off-label, low-dose naltrexone for refractory painful diabetic neuropathy. Pain Med. 2016;17:790\u20131.","journal-title":"Pain Med"},{"key":"3612_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.pmn.2020.12.014","volume":"22","author":"K Carolfi","year":"2021","unstructured":"Carolfi K, Nickasch BL. What do primary care providers and nurses need to know about managing chronic pain? Pain Manag Nurs. 2021;22:455\u20138.","journal-title":"Pain Manag Nurs"},{"key":"3612_CR40","first-page":"441","volume":"26","author":"JF de Carvalho","year":"2024","unstructured":"de Carvalho JF. Low-dose naltrexone as first option for fibromyalgia patients: a case series. Isr Med Assoc J. 2024;26:441\u20132.","journal-title":"Isr Med Assoc J"},{"key":"3612_CR41","first-page":"e83824","volume":"17","author":"U Moser","year":"2025","unstructured":"Moser U. Low-dose naltrexone for severe fibromyalgia syndrome: a report of a case with two-year follow-up. Cureus. 2025;17:e83824.","journal-title":"Cureus"},{"key":"3612_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1573397113666170321120329","volume":"14","author":"S Metyas","year":"2018","unstructured":"Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2018;14:177\u201380.","journal-title":"Curr Rheumatol Rev"},{"key":"3612_CR43","doi-asserted-by":"publisher","first-page":"e01475","DOI":"10.1213\/XAA.0000000000001475","volume":"15","author":"DL Neuman","year":"2021","unstructured":"Neuman DL, Chadwick AL. Utilization of low-dose naltrexone for burning mouth syndrome: a case report. A A Pract. 2021;15:e01475.","journal-title":"A A Pract"},{"key":"3612_CR44","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.oooo.2022.04.048","volume":"135","author":"L Sangalli","year":"2023","unstructured":"Sangalli L, Miller CS. Low-dose naltrexone for treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023;135:e83\u20138.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"3612_CR45","doi-asserted-by":"publisher","first-page":"e00677","DOI":"10.1016\/j.crwh.2024.e00677","volume":"45","author":"RT Sullender","year":"2025","unstructured":"Sullender RT, Silverstein RG, Goodwin DM, McClurg AB, Carey ET. Low-dose naltrexone as a treatment for vulvodynia: a case series. Case Rep Womens Health. 2025;45:e00677.","journal-title":"Case Rep Womens Health"},{"key":"3612_CR46","first-page":"99","volume":"6","author":"I Ruhoy","year":"2022","unstructured":"Ruhoy I, Koran LM. Low-dose naltrexone and pain relief in gadolinium deposition disease: a case series. Interv Pain Manag Rep. 2022;6:99\u2013102.","journal-title":"Interv Pain Manag Rep"},{"key":"3612_CR47","first-page":"109","volume":"5","author":"A Soin","year":"2021","unstructured":"Soin A. Management of pediatric complex regional pain syndrome with low-dose naltrexone. Pain Med Case Rep. 2021;5:109\u201313.","journal-title":"Pain Med Case Rep"},{"key":"3612_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/pme.12345","volume":"15","author":"B Ghai","year":"2014","unstructured":"Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. Pain Med. 2014;15:883\u20134.","journal-title":"Pain Med"},{"key":"3612_CR49","first-page":"30","volume":"20","author":"H Codino","year":"2021","unstructured":"Codino H, Hardin A. Low dose naltrexone in conjunction with the Wahls protocol to reduce the frequency of chronic migraines in a patient with multiple sclerosis: a case study. Integr Med. 2021;20:30\u20134.","journal-title":"Integr Med"},{"key":"3612_CR50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.36076\/pmcr.2023.7.377","volume":"7","author":"MT Lee","year":"2023","unstructured":"Lee MT, Eckmann MS. Retrospective analysis of naltrexone for persistent neuropathic pain case series. Pain Med Case Rep. 2023;7:377\u201383.","journal-title":"Pain Med Case Rep"},{"key":"3612_CR51","first-page":"682","volume":"56","author":"S Ananthan","year":"2025","unstructured":"Ananthan S, Heir G, Korczeniewska O. Use of low-dose naltrexone in the management of posttraumatic trigeminal neuropathic pain: a retrospective case series. Quintessence Int. 2025;56:682\u201390.","journal-title":"Quintessence Int"},{"key":"3612_CR52","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/pm\/pnaa001","volume":"21","author":"K Bruun-Plesner","year":"2020","unstructured":"Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med. 2020;21:2253\u201361.","journal-title":"Pain Med"},{"key":"3612_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.22006","volume":"68","author":"BAC Cree","year":"2010","unstructured":"Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010;68:145\u201350.","journal-title":"Ann Neurol"},{"key":"3612_CR54","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/1352458510366857","volume":"16","author":"N Sharafaddinzadeh","year":"2010","unstructured":"Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16:964\u20139.","journal-title":"Mult Scler"},{"key":"3612_CR55","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/1352458508095828","volume":"14","author":"M Gironi","year":"2008","unstructured":"Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14:1076\u201383.","journal-title":"Mult Scler"},{"key":"3612_CR56","first-page":"1","volume":"2","author":"MD Ludwig","year":"2016","unstructured":"Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016;2:1\u201311.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3612_CR57","first-page":"e4225","volume":"11","author":"S Zashin","year":"2019","unstructured":"Zashin S. Sjogren\u2019s syndrome: clinical benefits of low-dose naltrexone therapy. Cureus. 2019;11:e4225.","journal-title":"Cureus"},{"key":"3612_CR58","first-page":"e8948","volume":"12","author":"S Zashin","year":"2020","unstructured":"Zashin S. Sjogren\u2019s syndrome and clinical benefits of low-dose naltrexone therapy: additional case reports. Cureus. 2020;12:e8948.","journal-title":"Cureus"},{"key":"3612_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","volume":"47","author":"JP Smith","year":"2013","unstructured":"Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn\u2019s disease: a pilot study. J Clin Gastroenterol. 2013;47:339\u201345.","journal-title":"J Clin Gastroenterol"},{"key":"3612_CR60","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/ibd.21185","volume":"16","author":"A Shannon","year":"2010","unstructured":"Shannon A, Alkhouri N, Mayacy S, Kaplan B, Mahajan L. Low-dose naltrexone for treatment of duodenal Crohn\u2019s disease in a pediatric patient. Inflamm Bowel Dis. 2010;16:1457.","journal-title":"Inflamm Bowel Dis"},{"key":"3612_CR61","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","volume":"102","author":"JP Smith","year":"2007","unstructured":"Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn\u2019s disease. Am J Gastroenterol. 2007;102:820\u20138.","journal-title":"Am J Gastroenterol"},{"key":"3612_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12967-018-1427-5","volume":"16","author":"MRKL Lie","year":"2018","unstructured":"Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med. 2018;16:55.","journal-title":"J Transl Med"},{"key":"3612_CR63","first-page":"171","volume":"14","author":"J Ploesser","year":"2010","unstructured":"Ploesser J, Weinstock LB, Thomas E. Low dose naltrexone: side effects and efficacy in gastrointestinal disorders. Int J Pharm Compd. 2010;14:171\u20133.","journal-title":"Int J Pharm Compd"},{"key":"3612_CR64","first-page":"132","volume":"6","author":"KL Brewer","year":"2018","unstructured":"Brewer KL, Mainhart A, Meggs WJ. Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness. Fatigue. 2018;6:132\u201340.","journal-title":"Fatigue"},{"key":"3612_CR65","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.4103\/0028-3886.333523","volume":"69","author":"N Abokrysha","year":"2021","unstructured":"Abokrysha N, Kishk N, Nawito A, Mounir N. Effect of low-dose naltrexone on Egyptian children with intractable epilepsy: a case series study. Neurol India. 2021;69:1781\u20134.","journal-title":"Neurol India"},{"key":"3612_CR66","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.bbih.2022.100485","volume":"24","author":"B O\u2019Kelly","year":"2022","unstructured":"O\u2019Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485.","journal-title":"Brain Behav Immun Health"},{"key":"3612_CR67","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.clinthera.2023.12.009","volume":"46","author":"L Tamariz","year":"2024","unstructured":"Tamariz L, Bast E, Klimas N, Palacio A. Low-dose naltrexone improves post-COVID-19 condition symptoms. Clin Ther. 2024;46:e101\u20136.","journal-title":"Clin Ther"},{"key":"3612_CR68","doi-asserted-by":"publisher","first-page":"110966","DOI":"10.1016\/j.intimp.2023.110966","volume":"124","author":"H Bonilla","year":"2023","unstructured":"Bonilla H, Tian L, Marconi VC, et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Int Immunopharmacol. 2023;124:110966.","journal-title":"Int Immunopharmacol"},{"key":"3612_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/21501319241258671","volume":"15","author":"RT Hurt","year":"2024","unstructured":"Hurt RT, Yadav S, Schroeder DR, et al. Longitudinal progression of patients with long COVID treated in a post-COVID clinic: a cross-sectional survey. J Prim Care Community Health. 2024;15:1\u201311.","journal-title":"J Prim Care Community Health"},{"key":"3612_CR70","doi-asserted-by":"publisher","first-page":"100733","DOI":"10.1016\/j.bbih.2024.100733","volume":"36","author":"A Isman","year":"2024","unstructured":"Isman A, Nyquist A, Strecker B, et al. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain Behav Immun Health. 2024;36:100733.","journal-title":"Brain Behav Immun Health"},{"key":"3612_CR71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/21641846.2019.1692770","volume":"7","author":"O Polo","year":"2019","unstructured":"Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). Fatigue Biomed Health Behav. 2019;7:207\u201317.","journal-title":"Fatigue Biomed Health Behav"},{"key":"3612_CR72","doi-asserted-by":"publisher","first-page":"e232502","DOI":"10.1136\/bcr-2019-232502","volume":"13","author":"MJ Bolton","year":"2020","unstructured":"Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13:e232502.","journal-title":"BMJ Case Rep"},{"key":"3612_CR73","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/09546634.2020.1774488","volume":"33","author":"V Lajevardi","year":"2022","unstructured":"Lajevardi V, Salarvand F, Ghiasi M, Nasimi M, Taraz M. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial. J Dermatol Treat. 2022;33:769\u201373.","journal-title":"J Dermatol Treat"},{"key":"3612_CR74","first-page":"e34169","volume":"15","author":"RK Hamel","year":"2023","unstructured":"Hamel RK, Chen L, O\u2019Connell C, Mann C. Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: an uncontrolled open-label prospective study. Cureus. 2023;15:e34169.","journal-title":"Cureus"},{"key":"3612_CR75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaad.2024.03.010","volume":"91","author":"SM Yossef","year":"2024","unstructured":"Yossef SM, English JC. Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: a retrospective study. J Am Acad Dermatol. 2024;91:141\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"3612_CR76","first-page":"1140","volume":"16","author":"LC Strazzulla","year":"2017","unstructured":"Strazzulla LC, Avila L, Sicco KL, Shapiro J. Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol. 2017;16:1140\u20132.","journal-title":"J Drugs Dermatol"},{"key":"3612_CR77","doi-asserted-by":"publisher","first-page":"671","DOI":"10.36849\/JDD.6810","volume":"21","author":"EJ Klein","year":"2022","unstructured":"Klein EJ, Karim M, Kim R, Sicco KL, Shapiro J. Reversible hair loss in lichen planopilaris: regrowth with low-dose naltrexone and platelet-rich plasma. J Drugs Dermatol. 2022;21:671.","journal-title":"J Drugs Dermatol"},{"key":"3612_CR78","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/jamadermatol.2017.2446","volume":"153","author":"LN Albers","year":"2017","unstructured":"Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey disease with low-dose naltrexone. JAMA Dermatol. 2017;153:1018\u201320.","journal-title":"JAMA Dermatol"},{"key":"3612_CR79","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/bjd.16045","volume":"178","author":"V Campbell","year":"2018","unstructured":"Campbell V, McGrath C, Corry A. Low-dose naltrexone: a novel treatment for Hailey\u2013Hailey disease. Br J Dermatol. 2018;178:1196\u20138.","journal-title":"Br J Dermatol"},{"key":"3612_CR80","doi-asserted-by":"publisher","first-page":"e12892","DOI":"10.1111\/dth.12892","volume":"32","author":"M Garayar Cantero","year":"2019","unstructured":"Garayar Cantero M, Canseco Mart\u00edn M, Aguado Garc\u00eda \u00c1, Ruiz-S\u00e1nchez D, Valtue\u00f1a J, Manchado L\u00f3pez P. Use of low-dose naltrexone in the treatment of severe Hailey\u2013Hailey disease: one case report. Dermatol Ther. 2019;32:e12892.","journal-title":"Dermatol Ther"},{"key":"3612_CR81","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","volume":"153","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-dose naltrexone treatment of familial benign pemphigus (Hailey\u2013Hailey disease). JAMA Dermatol. 2017;153:1015\u20137.","journal-title":"JAMA Dermatol"},{"key":"3612_CR82","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1684\/ejd.2021.4162","volume":"31","author":"C Andrea","year":"2021","unstructured":"Andrea C, Breton AL, Kanitakis J. Dermpath & clinic: Hailey Hailey disease treated with low-dose naltrexone. Eur J Dermatol. 2021;31:675\u20136.","journal-title":"Eur J Dermatol"},{"key":"3612_CR83","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jdcr.2018.07.002","volume":"4","author":"N Kollman","year":"2018","unstructured":"Kollman N, Bass J. Generalized familial benign chronic pemphigus (Hailey\u2013Hailey disease) treated successfully with low-dose naltrexone. JAAD Case Rep. 2018;4:725\u20137.","journal-title":"JAAD Case Rep"},{"key":"3612_CR84","first-page":"19","volume":"13","author":"M Michael","year":"2020","unstructured":"Michael M, Benjamin MW, Shannon CT. Recalcitrant Hailey-Hailey disease successfully treated with low-dose naltrexone. J Clin Aesthet Dermatol. 2020;13:19\u201321.","journal-title":"J Clin Aesthet Dermatol"},{"key":"3612_CR85","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00404-020-05705-0","volume":"302","author":"M Sousa Gomes","year":"2020","unstructured":"Sousa Gomes M, Ara\u00fajo Pereira J, Trocado V, Prata JP, Teixeira V, Pinheiro P. Vulvar Hailey\u2013Hailey disease treated with low-dose naltrexone: case report and literature review. Arch Gynecol Obstet. 2020;302:1081\u20136.","journal-title":"Arch Gynecol Obstet"},{"key":"3612_CR86","first-page":"1","volume":"8","author":"D Lim","year":"2020","unstructured":"Lim D, Belisle A, Davar S. Improvement in Hailey\u2013Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: a case report. SAGE Open Med Case Rep. 2020;8:1\u20133.","journal-title":"SAGE Open Med Case Rep"},{"key":"3612_CR87","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jaad.2019.04.024","volume":"81","author":"C Riquelme-Mc Loughlin","year":"2019","unstructured":"Riquelme-Mc Loughlin C, Riera-Monroig J, Morgado-Carrasco D, et al. Low-dose naltrexone therapy in benign chronic pemphigus (Hailey\u2013Hailey disease): a case series. J Am Acad Dermatol. 2019;81:644\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"3612_CR88","doi-asserted-by":"publisher","first-page":"579","DOI":"10.29271\/jcpsp.2020.06.579","volume":"30","author":"S Khan","year":"2020","unstructured":"Khan S, Ghafoor R, Kaleem S. Efficacy of low dose naltrexone in psoriasis. J Coll Physicians Surg Pak. 2020;30:579\u201383.","journal-title":"J Coll Physicians Surg Pak"},{"key":"3612_CR89","first-page":"94","volume":"24","author":"LB Weinstock","year":"2020","unstructured":"Weinstock LB, Cottel J, Aldridge L, Egeberg A. Low-dose naltrexone therapy for psoriasis. Int J Pharm Compd. 2020;24:94\u20136.","journal-title":"Int J Pharm Compd"},{"key":"3612_CR90","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jdcr.2018.06.001","volume":"4","author":"AC Bridgman","year":"2018","unstructured":"Bridgman AC, Kirchhof MG. Treatment of psoriasis vulgaris using low-dose naltrexone. JAAD Case Rep. 2018;4:827\u20139.","journal-title":"JAAD Case Rep"},{"key":"3612_CR91","first-page":"270","volume":"22","author":"G Muller","year":"2018","unstructured":"Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D. Compounded low-dose naltrexone for the treatment of guttate psoriasis: a case report. Int J Pharm Compd. 2018;22:270\u20138.","journal-title":"Int J Pharm Compd"},{"key":"3612_CR92","first-page":"e3943","volume":"11","author":"EP Beltran Monasterio","year":"2019","unstructured":"Beltran Monasterio EP. Low-dose naltrexone: an alternative treatment for erythrodermic psoriasis. Cureus. 2019;11:e3943.","journal-title":"Cureus"},{"key":"3612_CR93","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/jdv.15457","volume":"33","author":"D Boehmer","year":"2019","unstructured":"Boehmer D, Eyerich K, Darsow U, Biedermann T, Zink A. Variable response to low-dose naltrexone in patients with Darier disease: a case series. J Eur Acad Dermatol Venereol. 2019;33:950\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3612_CR94","first-page":"177","volume":"84","author":"DL Smith-Pellegrin","year":"2021","unstructured":"Smith-Pellegrin DL, Rivera-Vega MR, Cazar\u00edn-Barrientos JR, Melgarejo-G\u00f3mez A, Messina-Baas OM, Cuevas-Covarrubias S. Naltrexone, a therapeutic alternative in Darier disease. Rev Med Hosp Gen Mex. 2021;84:177\u201380.","journal-title":"Rev Med Hosp Gen Mex"},{"key":"3612_CR95","first-page":"e33321","volume":"15","author":"T Costa","year":"2023","unstructured":"Costa T, Rebelo C, Marques Pinto G, Duarte B. Combination of naltrexone and isotretinoin for the treatment of Darier disease. Cureus. 2023;15:e33321.","journal-title":"Cureus"},{"key":"3612_CR96","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamadermatol.2024.4098","volume":"160","author":"ER Bray","year":"2024","unstructured":"Bray ER, Morrison BW. Low-dose naltrexone use in biopsy-proven lichen planus of the nails. JAMA Dermatol. 2024;160:1334\u20137.","journal-title":"JAMA Dermatol"},{"key":"3612_CR97","doi-asserted-by":"publisher","first-page":"804296","DOI":"10.1155\/2011\/804296","volume":"2011","author":"T Frech","year":"2011","unstructured":"Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011;2011:804296.","journal-title":"Int J Rheumatol"},{"key":"3612_CR98","doi-asserted-by":"publisher","first-page":"13030\/qt89b7555","DOI":"10.5070\/D3256044451","volume":"25","author":"AP Manudhane","year":"2019","unstructured":"Manudhane AP, Schrom KP, Ezaldein HH, Armile JA. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis. Dermatol Online J. 2019;25:13030\/qt89b75552.","journal-title":"Dermatol Online J"},{"key":"3612_CR99","doi-asserted-by":"publisher","first-page":"e12720","DOI":"10.1111\/dth.12720","volume":"31","author":"T Tran","year":"2018","unstructured":"Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone. Dermatol Ther. 2018;31:e12720.","journal-title":"Dermatol Ther"},{"key":"3612_CR100","doi-asserted-by":"publisher","first-page":"e243773","DOI":"10.1136\/bcr-2021-243773","volume":"14","author":"L Timoney","year":"2021","unstructured":"Timoney L, Bunker CB. Prurigo excori\u00e9e treated with low dose naltrexone. BMJ Case Rep. 2021;14:e243773.","journal-title":"BMJ Case Rep"},{"key":"3612_CR101","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jdcr.2023.06.012","volume":"38","author":"LC LaMonica","year":"2023","unstructured":"LaMonica LC, Lang-Houser M, Bresler SC, Mervak JE. Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus. JAAD Case Rep. 2023;38:82\u20135.","journal-title":"JAAD Case Rep"},{"key":"3612_CR102","first-page":"e55336","volume":"16","author":"K Varghese","year":"2024","unstructured":"Varghese K, Yan X, Cao F. Low-dose naltrexone for excoriation disorder. Cureus. 2024;16:e55336.","journal-title":"Cureus"},{"key":"3612_CR103","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","volume":"208","author":"D Mischoulon","year":"2017","unstructured":"Mischoulon D, Hylek L, Yeung AS, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6\u201314.","journal-title":"J Affect Disord"},{"key":"3612_CR104","doi-asserted-by":"publisher","first-page":"109438","DOI":"10.1016\/j.intimp.2022.109438","volume":"113","author":"PJ McLaughlin","year":"2022","unstructured":"McLaughlin PJ, Odom LB, Arnett PA, Orehek S, Thomas GA, Zagon IS. Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic. Int Immunopharmacol. 2022;113:109438.","journal-title":"Int Immunopharmacol"},{"key":"3612_CR105","first-page":"e22677","volume":"14","author":"J Siembida","year":"2022","unstructured":"Siembida J, Johnson B. Depression in fibromyalgia patients may require low-dose naltrexone to respond: a case report. Cureus. 2022;14:e22677.","journal-title":"Cureus"},{"key":"3612_CR106","first-page":"3463","volume":"30","author":"KB Peters","year":"2022","unstructured":"Peters KB, Affronti ML, Woodring S, et al. Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. Support Care Cancer. 2022;30:3463\u201371.","journal-title":"Support Care Cancer"},{"key":"3612_CR107","first-page":"973","volume":"34","author":"L Schwartz","year":"2014","unstructured":"Schwartz L, Buhler L, Icard P, Lincet H, Steyaert JM. Metabolic treatment of cancer: intermediate results of a prospective case series. Anticancer Res. 2014;34:973\u201380.","journal-title":"Anticancer Res"},{"key":"3612_CR108","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1534735405285901","volume":"5","author":"BM Berkson","year":"2006","unstructured":"Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic\/low-dose naltrexone protocol. Integr Cancer Ther. 2006;5:83\u20139.","journal-title":"Integr Cancer Ther"},{"key":"3612_CR109","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1534735407306358","volume":"6","author":"BM Berkson","year":"2007","unstructured":"Berkson BM, Rubin DM, Berkson AJ. Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone. Integr Cancer Ther. 2007;6:293\u20136.","journal-title":"Integr Cancer Ther"},{"key":"3612_CR110","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/1534735409352082","volume":"8","author":"BM Berkson","year":"2009","unstructured":"Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA\/N (alpha-lipoic acid\/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther. 2009;8:416\u201322.","journal-title":"Integr Cancer Ther"},{"key":"3612_CR111","first-page":"e2924","volume":"10","author":"JA Miskoff","year":"2018","unstructured":"Miskoff JA, Chaudhri M. Low dose naltrexone and lung cancer: a case report and discussion. Cureus. 2018;10:e2924.","journal-title":"Cureus"},{"key":"3612_CR112","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s10637-012-9918-3","volume":"31","author":"M Rogosnitzky","year":"2013","unstructured":"Rogosnitzky M, Finegold MJ, McLaughlin PJ, Zagon IS. Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Investig New Drugs. 2013;31:1066\u201370.","journal-title":"Investig New Drugs"},{"key":"3612_CR113","first-page":"e43426","volume":"15","author":"SJ Stallkamp Tidd","year":"2023","unstructured":"Stallkamp Tidd SJ, Cantrell C, Greene BD, Wilson R. Low-dose naltrexone use in postural orthostatic tachycardia syndrome: a case series. Cureus. 2023;15:e43426.","journal-title":"Cureus"},{"key":"3612_CR114","doi-asserted-by":"publisher","first-page":"bcr2017221405","DOI":"10.1136\/bcr-2017-221405","volume":"2018","author":"LB Weinstock","year":"2018","unstructured":"Weinstock LB, Brook JB, Myers TL, Goodman B. Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment. BMJ Case Rep. 2018;2018:bcr2017221405.","journal-title":"BMJ Case Rep"},{"key":"3612_CR115","first-page":"160","volume":"13","author":"D Rungkitwattanakul","year":"2025","unstructured":"Rungkitwattanakul D, Brooks M, Adesina S, et al. Extemporaneous preparation and effectiveness of low-dose naltrexone for the treatment of uremic pruritus: a literature review and case report. Pharmacy (Basel). 2025;13:160.","journal-title":"Pharmacy (Basel)"},{"key":"3612_CR116","first-page":"184","volume":"34","author":"LB Weinstock","year":"2017","unstructured":"Weinstock LB, Myers TL, Shetty A. Low-dose naltrexone for the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:184\u20137.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"3612_CR117","doi-asserted-by":"publisher","first-page":"109546","DOI":"10.1016\/j.mehy.2019.109546","volume":"137","author":"M Zappaterra","year":"2020","unstructured":"Zappaterra M, Shouse E, Levine RL. Low-dose naltrexone reduces symptoms in stiff-person syndrome. Med Hypotheses. 2020;137:109546.","journal-title":"Med Hypotheses"},{"key":"3612_CR118","first-page":"e77435","volume":"17","author":"A Britton","year":"2025","unstructured":"Britton A, Harinath G, Morgan S, Zalzala S. Unexpected increase in bone mineral density with rapamycin and low-dose naltrexone: a case report of a 52-year-old woman with osteopenia. Cureus. 2025;17:e77435.","journal-title":"Cureus"},{"key":"3612_CR119","doi-asserted-by":"publisher","first-page":"1789946","DOI":"10.1155\/2022\/1789946","volume":"2022","author":"GA Skulstad Johanson","year":"2022","unstructured":"Skulstad Johanson GA, Tysnes OB, Bjerknes TL. Use of off-label drugs and nutrition supplements among patients with amyotrophic lateral sclerosis in Norway. Neurol Res Int. 2022;2022:1789946.","journal-title":"Neurol Res Int"},{"key":"3612_CR120","doi-asserted-by":"publisher","first-page":"152","DOI":"10.30841\/2708-8731.6.2025.341017","volume":"85","author":"ZN Raffeq","year":"2025","unstructured":"Raffeq ZN, Hammo AHZSY. The effect of low-dose naltrexone on immunological infertility in women with recurrent implantation failure. Reprod Health Woman. 2025;85:152\u20139.","journal-title":"Reprod Health Woman"},{"key":"3612_CR121","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/S0140-6736(25)00672-5","volume":"405","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025;405:1633\u201340.","journal-title":"Lancet"},{"key":"3612_CR122","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1756-0500-7-264","volume":"7","author":"T Nissen","year":"2014","unstructured":"Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes. 2014;7:264.","journal-title":"BMC Res Notes"},{"key":"3612_CR123","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/healthcare9030330","volume":"9","author":"S McDonald","year":"2021","unstructured":"McDonald S, Nikles J. N-of-1 trials in healthcare. Healthcare (Basel). 2021;9:330.","journal-title":"Healthcare (Basel)"},{"key":"3612_CR124","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s11606-010-1352-7","volume":"25","author":"PA Scuffham","year":"2010","unstructured":"Scuffham PA, Nikles J, Mitchell GK, et al. Using N-of-1 trials to improve patient management and save costs. J Gen Intern Med. 2010;25:906\u201313.","journal-title":"J Gen Intern Med"}],"updated-by":[{"DOI":"10.1007\/s12325-026-03709-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03612-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03612-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03612-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:02:25Z","timestamp":1783494145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03612-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":124,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3612"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03612-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in article text.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03709-x","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03709-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amina HK\u00a0Gouda, Nicholas EC Aitcheson and Kathryn J Steadman declare no personal, financial, commercial or academic conflicts of interest and have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is a review of the published literature and does not involve the collection or analysis of primary data from human participants. As such, approval from a human research ethics committee was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}